Dermata (NASDAQ: DRMA) ends Nasdaq listing for warrants
Rhea-AI Filing Summary
Dermata Therapeutics, Inc. is having its warrant class removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states it has complied with its own rules to strike this class of securities, and the company has complied with exchange rules and SEC requirements governing voluntary withdrawal.
Positive
- None.
Negative
- None.
Key Terms
Form 25, Section 12(b) of the Securities Exchange Act of 1934, voluntary withdrawal of the class of securities from listing and registration
3 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
Section 12(b) of the Securities Exchange Act of 1934 regulatory
"REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"
voluntary withdrawal of the class of securities from listing and registration regulatory
"governing the voluntary withdrawal of the class of securities from listing"
FAQ
What does Dermata Therapeutics, Inc. (DRMA) report in this Form 25 filing?
Dermata Therapeutics reports that its warrant class is being removed from Nasdaq listing and Section 12(b) registration. Nasdaq and the company state they have complied with applicable exchange rules and SEC Rule 12d2-2 requirements for this withdrawal.
Which Dermata Therapeutics (DRMA) security is affected by this Nasdaq removal?
The filing covers Dermata Therapeutics’ warrants as the affected class of securities. It specifies that this warrant class is being struck from listing and withdrawn from registration on the Nasdaq Stock Market LLC under Section 12(b).
Who is the exchange involved in Dermata Therapeutics (DRMA) Form 25 delisting?
The exchange involved is the Nasdaq Stock Market LLC. Nasdaq certifies it has reasonable grounds to file Form 25 and that it has followed its rules to strike Dermata’s warrant class from listing and registration under Section 12(b).
Is the Dermata Therapeutics (DRMA) warrant removal from Nasdaq voluntary?
The filing states that, under 17 CFR 240.12d2-2(c), the issuer has complied with the exchange’s rules and SEC requirements governing the voluntary withdrawal of this warrant class from listing and registration on Nasdaq.
What SEC rules are cited in Dermata Therapeutics (DRMA) Form 25?
The notification references 17 CFR 240.12d2-2(a), 12d2-2(b), and 12d2-2(c). These provisions govern how exchanges and issuers remove a class of securities from listing and withdraw registration under Section 12(b) of the Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
